Illumina, Inc. (ILMN)
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina (ILMN) Moves to Strong Buy: Rationale Behind the Upgrade
Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Illumina, Inc. (ILMN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Illumina, Inc. ( ILMN ) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 9:20 AM EST Company Participants Jacob Thaysen - CEO & Director Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC Okay. Good morning, everybody.
Illumina, Inc. (ILMN) Q3 2025 Earnings Call Transcript
Illumina, Inc. ( ILMN ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Conor Noel McNamara - VP of Investor Relations Jacob Thaysen - CEO & Director Ankur Dhingra - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Douglas Schenkel - Wolfe Research, LLC Vijay Kumar - Evercore ISI Institutional Equities, Research Division Tycho Peterson - Jefferies LLC, Research Division Daniel Leonard - UBS Investment Bank, Research Division Patrick Donnelly - Citigroup Inc., Research Division Mason Carrico - Stephens Inc., Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Jack Meehan - Nephron Research LLC Daniel Brennan - TD Cowen, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Presentation Operator Good day, ladies and gentlemen.
Compared to Estimates, Illumina (ILMN) Q3 Earnings: A Look at Key Metrics
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Illumina (ILMN) Beats Q3 Earnings and Revenue Estimates
Illumina (ILMN) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.14 per share a year ago.
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina: Innovation Outweighs Short-Term Risks - A Long-Term Buy Ahead Of Q3 Earnings
Illumina is at a pivotal moment, balancing near-term challenges with innovations in multiomics, AI, and proteomics to redefine its growth trajectory. ILMN's planned SomaLogic acquisition and new AI-driven initiatives like BioInsight strengthen its multiomics strategy and expand high-margin revenue streams. Despite competition and risks from China and regulatory pressures, ILMN maintains strong clinical growth, robust cash flow, and a leading market position.
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
ILMN Stock Set to Benefit From the Launch of New BioInsight Division
Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
